Phase I and pharmacologic study of liposomal lurtotecan, NX 211: Urinary excretion predicts hematologic toxicity

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1222-1231

  Kehrer, Diederik F S ^a   Bos, Annelies M ^a   Verweij, Jaap ^a   Groen, Harry J ^a   Loos, Walter J ^a   Sparreboom, Alex ^a   de Jonge, Maja J A ^a   Hamilton, Marta ^a   Cameron, Terri ^a   de Vries, Elisabeth G E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; LURTOTECAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EXCRETION; DRUG STRUCTURE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY EXCRETION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0036499054     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1222     Document Type: Article

References (27)

1. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I
2. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development
3. Modulation of camptothecin analogues in the treatment of cancer: A review
4. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues
5. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily ×5 intravenous administration
6. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks
7. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study
8. Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG)
9. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion
10. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion
11. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
12. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine
13. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan
14. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions
15. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11
16. Effective irinotecan (CPT-11)containing liposomes: Intraliposomal conversion to the active metabolite SN-38
17. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts
18. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models
19. Designing therapeutically optimized liposomal anti-cancer delivery systems: Lessons from conventional liposomes
20. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan
21. Liposomal lurtotecan (NX 211): Determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography
22. Phase I evaluation of liposomal topoisomerase I inhibitor, NX 211, given on days 1, 2, 3 or days 1, 8 every 3 weeks to patients (pts) with advanced solid tumors
23. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia
24. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin
25. Phase I study of liposomal vincristine
26. Identification and biological activity of 7-ethyl-10, 11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan